NEW YORK (GenomeWeb News) — Emiliem and Invitrogen will screen Emiliem’s multi-kinase inhibitors under a partnership agreement, the companies said today.
The companies said they will use Invitrogen’s SelectScreen for kinase and P450 screening and cellular pathway profiling to study Emiliem’s cancer compounds.  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.